Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Vitamin D, K2, Magnesium and Zinc.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, women only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

Groups ran in parallel: each of the participants stayed in one arm throughout.

A follow-up of a double-blind, placebo-controlled study conducted at Sahlgrenska University Hospital was performed.

What Was Measured

PubMed files the paper under topics including Bone Density, Calcium, Fractures, Bone, Human Growth Hormone, Incidence, Osteoporosis, Postmenopausal and Quality of Life.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.